title: [Pharmacogenomics in routine medical care].
abstract: Pharmacogenomics investigates inherited differences in drug responses including beneficial and adverse reactions. While a considerable amount of evidence for genetic influences on drug responses has been accumulated within the last decade, predominantly in small studies, its value in routine therapy is still a matter of debate. The aim of this review is to discuss well established examples where pharmacogenomic techniques can improve routine treatment. Examples include genotyping of CYP2D6 in the context of antidepressant therapy, analysis of TPMT variants for the prediction of mercaptopurine-induced bone marrow depression, VKORC1 and CYP2C9 analyses for a better control of anticoagulant administration and the SLCO1B1 variant in the context of statin-induced myopathies.
authors.affiliation: Institut für Pharmakologie, Ernst-Moritz-Arndt Universität, Greifswald.
authors.forename: D
authors.initials: D
authors.lastname: Rosskopf
authors.forename: H E
authors.initials: HE
authors.lastname: Meyer zu Schwabedissen
authors.forename: H K
authors.initials: HK
authors.lastname: Kroemer
authors.forename: W
authors.initials: W
authors.lastname: Siegmund
mesh_terms: D000293:Adolescent; D000328:Adult; D000483:Alleles; D000924:Anticholesteremic Agents / Q000493:pharmacokinetics / Q000633:toxicity; D000925:Anticoagulants / Q000493:pharmacokinetics / Q000633:toxicity; D000996:Antitussive Agents / Q000493:pharmacokinetics / Q000633:toxicity; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001682:Biological Availability; D001711:Biotransformation / Q000235:genetics; D003061:Codeine / Q000493:pharmacokinetics / Q000633:toxicity; D065729:Cytochrome P-450 CYP2C9; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D051544:Cytochrome P-450 CYP3A / Q000235:genetics; D065692:Cytochrome P-450 CYP3A Inhibitors; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D027381:Liver-Specific Organic Anion Transporter 1; D008297:Male; D008657:Metabolic Clearance Rate / Q000235:genetics; D008780:Methyltransferases / Q000172:deficiency / Q000235:genetics; D008875:Middle Aged; D009294:Narcotics / Q000493:pharmacokinetics / Q000633:toxicity; D027361:Organic Anion Transporters / Q000235:genetics; D010597:Pharmacogenetics; D010641:Phenotype; D010644:Phenprocoumon / Q000493:pharmacokinetics / Q000633:toxicity; D017354:Point Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics; D057285:Precision Medicine; D019821:Simvastatin / Q000493:pharmacokinetics / Q000633:toxicity; D014859:Warfarin / Q000493:pharmacokinetics / Q000633:toxicity
chemical_list: D000924:Anticholesteremic Agents; D000925:Anticoagulants; D000996:Antitussive Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D009294:Narcotics; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D014859:Warfarin; D019821:Simvastatin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D010644:Phenprocoumon; D003061:Codeine